|
|
Background: This study investigated the expression and clinical significance of coiled-coil domain containing 12 (CCDC12) in the initial diagnosis of acute myeloid leukemia (AML).
Methods: A total of 80 AML patients were enrolled as the experimental group, and 20 normal bone marrow specimens were used as the control group. Clinical data of AML patients were collected. The expression level of CCDC12 was measured using real-time fluorescent quantitative PCR (QRT-PCR) in both groups. The relationship between CCDC12 expression and clinical pathological characteristics and prognosis in AML patients was analyzed. Kaplan-Meier curves were used to evaluate the effect of CCDC12 expression on overall survival (OS) in AML patients, while Cox proportional hazards regression analysis was performed to assess prognosis.
Results: CCDC12 expression was significantly higher in AML patients compared to the control group (p < 0.05). Patients in the high CCDC12 expression group were older, had higher platelet counts (PLT), poorer treatment responses, and worse prognoses, with statistically significant differences (p < 0.05). The OS in the high CCDC12 expression group was significantly shorter (p < 0.05). High CCDC12 expression was identified as an independent risk factor for poor AML prognosis.
Conclusions: CCDC12 is highly expressed in AML patients. Elevated CCDC12 expression is associated with unfavorable clinical pathological characteristics and poor prognosis. This marker may provide a new approach for the diagnosis, monitoring, and targeted therapy of AML.
DOI: 10.7754/Clin.Lab.2024.241015
|
